Clinical trials: Colon Cancer Stage II
Brain Metastasis, Bladder Cancer
Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases
For patients who have one or two metastases in the brain, the tumor(s) can often be removed with surgery to relieve symptoms from the tumor(s) and to improve survival.
- Conditions
- Brain Metastasis, Bladder Cancer, Breast Cancer, Cervical Cancer
- Trial name
- NCT00587964
- Testing
- Stereotactic Radiosurgery
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Colorectal Cancer
Study of Gamma Interfereon in Metastatic Colorectal Carcinoma
The purpose of this study is to evalute the response and toxicity of metastatic colorectal cancer patients to the regimen of gamma interferon added to bolus and infusional 5-fluorouracil and leucovorin (GFL) with or without…
- Trial name
- GFL (NCT00786643)
- Testing
- 5-Fluorouracil, Leucovorin (LV), Gamma-Interferon-1b (IFN-γ)
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Accelerated Community Oncology Research Network
Colorectal Cancer
Phase I/II Study of KRN330 Plus Irinotecan in Patients With Metastatic Colorectal Cancer
The primary objective of the Phase II portion of this study is to assess the efficacy of KRN330 in combination with irinotecan after first-line or adjuvant FOLFOX (5-fluorouracil, leucovorin, and oxaliplatin)/CapOx (capecitabine…
- Trial name
- NCT00838578
- Testing
- KRN330, Irinotecan
- Where
- 12 sites in United States
- Volunteers
- 65 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Colorectal Cancer
Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer
RATIONALE: Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as panitumumab, can block tumor growth in different ways.
- Trial name
- NCT00940316
- Testing
- panitumumab, erlotinib hydrochloride, irinotecan hydrochloride
- Where
- 10 sites in United States
- Volunteers
- 28 people
- Sponsor
- Northwestern University
Colorectal Cancer
Cetuximab and Capecitabine in Treating Patients With Metastatic Colorectal Cancer That Failed Irinotecan Treatment
RATIONALE: Monoclonal antibodies such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00538291
- Testing
- cetuximab, capecitabine, gene expression analysis
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- City of Hope Medical Center
Colorectal Cancer
Azacitidine and CAPOX in Metastatic Colorectal Cancer
The goal of the Phase I portion of this study is to find the highest tolerable dose of azacitidine combined with capecitabine and oxaliplatin (CAPOX) that can be given to patients with metastatic colorectal cancer.
- Trial name
- NCT01193517
- Testing
- Azacitidine, Capecitabine, Oxaliplatin
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- M.D. Anderson Cancer Center
Non-Small Cell Lung Cancer, Colorectal Cancer
Study of Dovitinib and Biomarkers in Advanced Non-Small Cell Lung Cancer or Advanced Colorectal Cancer
The purpose of this study is to find out if dovitinib is an effective treatment for patients with advanced lung cancer or advanced colorectal cancer (CRC) who have progressed on anti-vascular endothelial growth factor (VEGF)…
- Trial name
- NCT01676714
- Testing
- Dovitinib
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of California, Davis
Metastatic Colorectal Cancer
Safety, Tolerability and Efficacy of Regorafenib in Combination With FOLFIRINOX in Patients With Colorectal Cancer
Safety, tolerability and efficacy of regorafenib in combination with FOLFIRINOX in patients with RAS-mutated metastatic colorectal cancer: a dose-escalation, phase I/II trial
- Trial name
- FOLFIRINOX-R (NCT03828799)
- Testing
- Folfirinox + regorafenib
- Where
- 4 sites in France
- Volunteers
- 13 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Gastrointestinal Cancer
RAD001 and AV-951 in Patients With Refractory, Metastatic Colorectal Cancer
Research has shown that anti-angiogenic agents can be effective therapies to treat cancer. Anti-angiogenic agents target the blood vessels required for tumors to grow.
- Trial name
- NCT01058655
- Testing
- Everolimus, Tivozanib
- Where
- 3 sites in United States
- Volunteers
- 56 people
- Sponsor
- Dana-Farber Cancer Institute
Metastatic Colorectal Cancer
Durvalumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer
The POLE mutations represent high somatic mutation loads in patients with colorectal cancer, especially in those with MMR proficient or MSS, therefore, tumors harbouring POLE mutations might be susceptible to immune checkpoint…
- Trial name
- NCT03435107
- Testing
- Durvalumab
- Where
- South Korea
- Volunteers
- 33 people
- Sponsor
- Asan Medical Center
Metastatic Colorectal Cancer
A Phase II Randomized Therapeutic Optimization Trial for Subjects With Refractory Metastatic Colorectal Cancer Using ctDNA: Rapid 1 Trial
This randomized, phase 2 study will investigate the use of the Signatera ctDNA assay versus the standard scan-based approach to guide treatment in patients with metastatic colorectal cancer.
- Trial name
- NCT04786600
- Testing
- Signatera ctDNA assay, pre-specified sequence of FDA-approved drugs and drug combinations
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Florida
Colorectal Cancer, Lung Cancer
QUILT-3.038: Active Immunotherapy CEA Vaccine in Patients With Malignancies Expressing CEA
The purpose of this study is to find out what effects (good and bad) that a cancer vaccine has on you and your cancer. The cancer vaccine is called Ad5 [E1-, E2b-]-CEA(6D)or ETBX-011 and is made by Etubics.
- Conditions
- Colorectal Cancer, Lung Cancer, Breast Cancer, Prostate Cancer
- Trial name
- NCT01147965
- Testing
- Ad5 CEA Vaccine
- Where
- 2 sites in United States
- Volunteers
- 43 people
- Sponsor
- NantCell, Inc.
Colorectal Cancer, Colorectal Carcinoma
A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer
Background: Immune-based approaches in colorectal cancer have unfortunately with the notable exception of immune checkpoint inhibition in microsatellite instable (MSI-hi) disease been largely unsuccessful.
- Conditions
- Colorectal Cancer, Colorectal Carcinoma, Colorectal Adenocarcinoma, Refractory Cancer
- Trial name
- NCT03206073
- Testing
- Durvalumab, Tremelimumab, Pexa-Vec
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
The purpose of this study is to see if Cediranib in combination with FOLFOX is effective in treating metastatic colorectal cancer and to see how it compares with Avastin (Bevacizumab) in combination with FOLFOX.
- Trial name
- HORIZON III (NCT00384176)
- Testing
- Cediranib, Bevacizumab, 5-fluorouracil ( in FOLFOX)
- Where
- 280 sites in United States, Australia and 26 more
- Volunteers
- 1,814 people
- Sponsor
- AstraZeneca
BRAF V600E, Metastatic Colorectal Cancer
A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer.
Encorafenib is currently being developed (with or without binimetinib), in combination with cetuximab, for the treatment of adult patients with B-RAF proto-oncogene, serine/threonine kinase V600E mutant (BRAF V600E) metastatic…
- Trial name
- NAUTICALCRC (NCT05004350)
- Testing
- Encorafenib, Cetuximab, FOLFIRI
- Where
- 34 sites in China
- Volunteers
- 107 people
- Sponsor
- Pierre Fabre Medicament
BRAF V600E-mutant Metastatic Colorectal Cancer
Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer
The purpose of this study is to evaluate the efficacy and safety of the combination of study drugs encorafenib, binimetinib and cetuximab in patients who have BRAF V600 mutant metastatic colorectal cancer and have not received…
- Trial name
- ANCHOR-CRC (NCT03693170)
- Testing
- encorafenib, Binimetinib, Cetuximab
- Where
- 45 sites in United States, Austria and 7 more
- Volunteers
- 95 people
- Sponsor
- Pierre Fabre Medicament
Anal Cancer, Carcinoma of the Appendix
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
RATIONALE: Palonosetron hydrochloride may prevent nausea and vomiting caused by radiation therapy. It is not yet known whether palonosetron hydrochloride is more effective than a placebo in preventing nausea and vomiting.
- Conditions
- Anal Cancer, Carcinoma of the Appendix, Colorectal Cancer, Extrahepatic Bile Duct Cancer
- Trial name
- NCT00903396
- Testing
- palonosetron hydrochloride
- Where
- 69 sites in United States
- Volunteers
- 7 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Colorectal Cancer
Ginger for Colorectal Cancer Prevention
The purpose of this study is to determine if ginger root extract when taken daily for 28 days is able to decrease levels of inflammatory chemicals called eicosanoids in the gut tissue of people who are at normal risk and those at…
- Trial name
- NCT01344538
- Testing
- Ginger Root Extract (Pure Encapsulations)
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Colon Adenocarcinoma, Stage IIA Colon Cancer AJCC v7
Fluorouracil, Leucovorin, and Oxaliplatin With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II or Stage III Colon Cancer
This randomized phase III trial is studying giving oxaliplatin, leucovorin, and fluorouracil together with bevacizumab to see how well it works compared to oxaliplatin, leucovorin, and fluorouracil alone in treating patients who…
- Conditions
- Colon Adenocarcinoma, Stage IIA Colon Cancer AJCC v7, Stage IIB Colon Cancer AJCC v7, Stage IIC Colon Cancer AJCC v7
- Trial name
- NCT00096278
- Testing
- Bevacizumab, Fluorouracil, Leucovorin Calcium
- Where
- United States
- Volunteers
- 2,710 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Colorectal Cancer
A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC
This is a multi-center Phase II randomized study. We plan to enroll 78 patients with biopsy-proven hepatic-limited metastatic colorectal cancer deemed resectable after multi-disciplinary discussion.
- Trial name
- NCT03547999
- Testing
- mFOLFOX6, MVA-BN-CV301, FPV-CV301
- Where
- 7 sites in United States
- Volunteers
- 17 people
- Sponsor
- Patrick Boland